abstract |
The present invention relates to the use of benzylideneaminoguanidines of the general formula (I) as melanocortin receptor agonists or antagonists, and in particular benzylideneamino which shows selectivity as agonists and / or antagonists for the MC1 and MC4 melanocortin receptors. Regarding the use of guanidine. |